Department of Gastroenterology, Dongyang People's Hospital of Zhejiang Province, Jinhua City, 322100, Zhejiang Province, China.
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital & Chongqing Cancer Institute, No. 181 Hanyu Road, Shapingba District, Chongqing, 400030, China.
Mol Cell Biochem. 2022 Sep;477(9):2149-2159. doi: 10.1007/s11010-020-03738-2. Epub 2020 Apr 27.
The aim of this study is to assess the expression levels of SMYD2 in human tissue samples and cells of colon cancer, and further explore the potential mechanisms of SMYD2 in colon cancer progression. Quantitative PCR and Immunohistochemical (IHC) assays were performed to detect SMYD2 expression in 76 tissue samples of colon cancer tissues and the corresponding normal tissues. The potential correlations between SMYD2 expression levels and clinical pathological features were assessed. We further detected the effects of SMYD2 on the proliferation, invasion and apoptosis of colon cancer cells and on ERBB2/FUT4 signaling pathway through Brdu assay, transwell assay and flow cytometry assay, respectively. The potential effects of SMYD2 on tumor growth were explored using an animal model. We demonstrated the possible involvement of SMYD2 in the progression of colon cancer. We found the high expression of SMYD2 in human colon cancer tissues and cells, and found the correlations between SMYD2 expression and the clinicopathological features including vascular invasion (P = 0.007*), TNM stage (P = 0.016*) and lymph node metastasis (P = 0.011*), of patients with colon cancer. Our data further confirmed that SMYD2 affects cell proliferation, invasion, and apoptosis of colon cancer cells via the regulation of ERBB2/FUT4 signaling pathway. We also demonstrated SMYD2 contributed to tumor growth of colon cancer cells in vivo. We investigated the potential involvement of SMYD2 in the progression of colon, and therefore confirmed SMYD2 as a possible therapeutic target for colon cancer.
本研究旨在评估 SMYD2 在人结肠癌组织样本和细胞中的表达水平，并进一步探讨 SMYD2 在结肠癌进展中的潜在机制。通过定量 PCR 和免疫组织化学（IHC）检测 76 例结肠癌组织和相应正常组织中 SMYD2 的表达。评估 SMYD2 表达水平与临床病理特征之间的潜在相关性。我们进一步通过 Brdu 检测、Transwell 检测和流式细胞术检测，分别检测 SMYD2 对结肠癌细胞增殖、侵袭和凋亡的影响，以及对 ERBB2/FUT4 信号通路的影响。通过动物模型探讨 SMYD2 对肿瘤生长的潜在影响。我们证明了 SMYD2 可能参与了结肠癌的进展。我们发现 SMYD2 在人结肠癌组织和细胞中高表达，并发现 SMYD2 表达与包括血管侵犯（P=0.007*）、TNM 分期（P=0.016*）和淋巴结转移（P=0.011*）在内的结肠癌患者的临床病理特征之间存在相关性。我们的数据进一步证实，SMYD2 通过调节 ERBB2/FUT4 信号通路影响结肠癌细胞的增殖、侵袭和凋亡。我们还证明了 SMYD2 在体内促进结肠癌细胞的肿瘤生长。我们研究了 SMYD2 在结肠癌进展中的潜在作用，因此证实 SMYD2 可能是结肠癌的一个潜在治疗靶点。
